Will GLP-1-based therapies substitute sulfonylureas?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1607, 2007-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GLP-1-based therapies yet to reach their peak potential

Inpharma, Vol. 1, Iss. 1656, 2008-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

GLP-2 beneficial in functional short bowel syndrome?

Inpharma, Vol. 1, Iss. 1284, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Substitute ACE inhibitors with valsartan in HF?

Inpharma, Vol. 1, Iss. 1363, 2002-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

Current Pharmaceutical Design, Vol. 17, Iss. 38, 2011-01 ,pp. : 4379-4385

Bentham Science Publishers

Access to resources Recommend Favorite

RRM1-based tailored chemotherapy for NSCLC?

Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite